RIZ1: a potential tumor suppressor in glioma

BMC Cancer

Table 1 Correlation between RIZ1 immunoreactivity and clinicopathologic features

		RIZ1 immunoreactivity (Median = 8.0)
Features	N(N = 51, %)	<Median	≥Median	P-values
Gender				0.097
Male	32(62.7)	19	13
Female	19(37.3)	6	13
Age				0.027*
< 50 years	29(56.9)	12	17
≥ 50 years	22(43.1)	13	9
Tumor diameter				0.324
< 6 cm	32(62.7)	14	18
≥ 6 cm	19(37.3)	11	8
Extent of resection				0.436
Gross-total	39(76.5)	20	19
Sub-total	12(23.5)	5	7
Pathological grade				0.000*
Low grade	12(23.5)	1	11
High grade	39(76.5)	24	15
Ki-67 immunoreactivity
< Median	24(47.1)
≥ Median	27(52.9)

* P < 0.05 was considered statistically significant
Table 1: Clinicopathological evaluation suggested that RIZ1 expression was associated with tumor grade (p = 0.000) and patient age (P = 0.027)

ISSN: 1471-2407